阳光诺和：STC007注射液针对术后疼痛的临床试验正在按既定方案稳步推进

Group 1 - The core viewpoint of the article is that Yangguang Nuohuo is making steady progress in the clinical trials of STC007 injection for postoperative pain management, with developments aligning with expectations [2] - The company indicated that the timeline for the market application will be determined based on clinical trial data results, statistical analysis, and registration preparation [2] - In the current market landscape for postoperative pain treatment in China, traditional analgesics dominate, while STC007 targets kappa opioid receptors (KOR) and offers advantages such as reduced central nervous system side effects and longer analgesic duration [2] Group 2 - STC007's unique mechanism and safety advantages address unmet clinical needs, with only one other product targeting the same receptor currently on the market and included in the medical insurance directory [2] - The company will continue to monitor industry competition dynamics and focus on the clinical value and commercialization of its products, with relevant competitive information to be based on public industry reports and company announcements [2]